Jefferies Financial Group Inc. Takes Position in MacroGenics, Inc. $MGNX

Jefferies Financial Group Inc. purchased a new stake in MacroGenics, Inc. (NASDAQ:MGNX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,841,172 shares of the biopharmaceutical company’s stock, valued at approximately $2,964,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Leonteq Securities AG purchased a new stake in shares of MacroGenics in the 4th quarter valued at approximately $161,000. GSA Capital Partners LLP raised its stake in shares of MacroGenics by 740.5% in the 4th quarter. GSA Capital Partners LLP now owns 511,004 shares of the biopharmaceutical company’s stock valued at $823,000 after acquiring an additional 450,203 shares during the period. AlphaCore Capital LLC purchased a new stake in MacroGenics during the 4th quarter worth approximately $61,000. R Squared Ltd purchased a new stake in MacroGenics during the 4th quarter worth approximately $26,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in MacroGenics by 42.9% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 300,000 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 90,000 shares during the period. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Stock Down 1.3%

NASDAQ MGNX opened at $4.47 on Wednesday. The firm has a 50 day moving average of $3.39 and a two-hundred day moving average of $2.31. MacroGenics, Inc. has a 52 week low of $1.18 and a 52 week high of $4.64. The stock has a market capitalization of $284.11 million, a PE ratio of -4.06 and a beta of 1.08.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.01). MacroGenics had a negative return on equity of 147.80% and a negative net margin of 44.79%.The company had revenue of $20.78 million for the quarter, compared to analyst estimates of $15.24 million. On average, equities research analysts expect that MacroGenics, Inc. will post -1.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MGNX shares. Wall Street Zen raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Citigroup reaffirmed a “market perform” rating on shares of MacroGenics in a research note on Tuesday, February 24th. B. Riley Financial raised shares of MacroGenics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $3.00 to $9.00 in a research note on Friday, April 10th. Barclays upped their target price on shares of MacroGenics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Monday, April 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a research note on Friday, May 8th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $5.50.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.